BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 27,000 Shares

Posted by Brenda Bartman on Oct 9th, 2026

BioNTech SE Sponsored ADR (NASDAQ:BNTX – Get Free Report) CEO Ugur Sahin sold 27,000 shares of the business’s stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $92.31, for a total value of $2,492,370.00. Following the completion of the transaction, the chief executive officer directly owned 36,209 shares in the company, valued at approximately $3,342,452.79. This trade represents a 42.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

On Friday, October 9th, Ugur Sahin sold 36,209 shares of BioNTech stock. The stock was sold at an average price of $95.37, for a total transaction of $3,453,252.33.
On Wednesday, October 7th, Ugur Sahin sold 24,000 shares of BioNTech stock. The stock was sold at an average price of $95.86, for a total transaction of $2,300,640.00.
On Tuesday, October 6th, Ugur Sahin sold 21,000 shares of BioNTech stock. The stock was sold at an average price of $96.81, for a total transaction of $2,033,010.00.
On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The shares were sold at an average price of $97.23, for a total value of $7,000,560.00.
On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The stock was sold at an average price of $97.46, for a total value of $1,656,820.00.
On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total transaction of $3,139,840.00.
On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.47, for a total transaction of $3,347,980.00.
On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $98.69, for a total transaction of $2,664,630.00.
On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total value of $3,860,610.00.
On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00.

BioNTech Stock Up 5.3%

Shares of BNTX stock traded up $4.90 on Friday, hitting $96.96. The stock had a trading volume of 1,288,649 shares, compared to its average volume of 1,088,842. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The business has a 50 day moving average of $99.04 and a 200 day moving average of $95.16. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The stock has a market cap of $24.52 billion, a price-to-earnings ratio of -12.38 and a beta of 1.25.

BioNTech (NASDAQ:BNTX – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. During the same period in the previous year, the business posted ($1.60) earnings per share. The business’s revenue was down 59.5% compared to the same quarter last year. As a group, analysts expect that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Morgan Stanley cut their target price on shares of BioNTech from $115.00 to $114.00 and set an “overweight” rating for the company in a research report on Wednesday. Canaccord Genuity Group cut their price objective on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a report on Monday, August 31st. Argus started coverage on shares of BioNTech in a report on Thursday. They set a “hold” rating on the stock. Berenberg Bank set a $140.00 target price on BioNTech in a research report on Wednesday, September 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a report on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $125.69.

Get Our Latest Research Report on BNTX

Institutional Investors Weigh In On BioNTech

Several hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC lifted its holdings in BioNTech by 31.5% in the third quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock worth $48,000 after buying an additional 118 shares during the period. Quintet Private Bank Europe S.A. boosted its position in shares of BioNTech by 232.8% during the third quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company’s stock valued at $188,000 after purchasing an additional 1,341 shares in the last quarter. Engineers Gate Manager LP boosted its position in shares of BioNTech by 17.3% during the second quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock valued at $1,157,000 after purchasing an additional 1,833 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in BioNTech in the second quarter worth $39,000. Finally, Nykredit A S purchased a new stake in BioNTech in the second quarter worth $293,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

(Get Free Report)

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.